The partnership will leverage Leica BOND automated advanced staining systems and pair with one of Synthon Biopharmaceutical’s antibody-drug conjugates (ADCs) to enhance the treatment of solid tumors.

Leica Biosystems president Matthias Weber said the company is pleased to be working with Synthon Biopharmaceuticals on cancer therapies with the Leica BOND platform.

"This partnership with Synthon is the next example of our commitment to provide unique tests to support the management of cancer patients," Weber added.

"The ease of use and high staining quality of our BOND systems makes them ideal platforms on which to deploy these very informative tests."